- Main
Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy
- Fozouni, Parinaz;
- Son, Sungmin;
- Díaz de León Derby, María;
- Knott, Gavin J;
- Gray, Carley N;
- D'Ambrosio, Michael V;
- Zhao, Chunyu;
- Switz, Neil A;
- Kumar, G Renuka;
- Stephens, Stephanie I;
- Boehm, Daniela;
- Tsou, Chia-Lin;
- Shu, Jeffrey;
- Bhuiya, Abdul;
- Armstrong, Maxim;
- Harris, Andrew R;
- Chen, Pei-Yi;
- Osterloh, Jeannette M;
- Meyer-Franke, Anke;
- Joehnk, Bastian;
- Walcott, Keith;
- Sil, Anita;
- Langelier, Charles;
- Pollard, Katherine S;
- Crawford, Emily D;
- Puschnik, Andreas S;
- Phelps, Maira;
- Kistler, Amy;
- DeRisi, Joseph L;
- Doudna, Jennifer A;
- Fletcher, Daniel A;
- Ott, Melanie
- et al.
Published Web Location
https://doi.org/10.1016/j.cell.2020.12.001Abstract
The December 2019 outbreak of a novel respiratory virus, SARS-CoV-2, has become an ongoing global pandemic due in part to the challenge of identifying symptomatic, asymptomatic, and pre-symptomatic carriers of the virus. CRISPR diagnostics can augment gold-standard PCR-based testing if they can be made rapid, portable, and accurate. Here, we report the development of an amplification-free CRISPR-Cas13a assay for direct detection of SARS-CoV-2 from nasal swab RNA that can be read with a mobile phone microscope. The assay achieved ∼100 copies/μL sensitivity in under 30 min of measurement time and accurately detected pre-extracted RNA from a set of positive clinical samples in under 5 min. We combined crRNAs targeting SARS-CoV-2 RNA to improve sensitivity and specificity and directly quantified viral load using enzyme kinetics. Integrated with a reader device based on a mobile phone, this assay has the potential to enable rapid, low-cost, point-of-care screening for SARS-CoV-2.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-